Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Dandrit Biotech A/S Signs Agreement To Commence Clinical Trials Of Melcancervac®

DanDrit Biotech A/S ("DanDrit Denmark"), the subsidiary of DanDrit Biotech USA, Inc. ("DanDrit"), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, signed a contract of collaboration with the University Hospital IRCCS "San Martino" - IST – National Institute for Cancer Research known as the San Martino Hospital of Genoa.

30 Sep 2014

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.

30 Sep 2014

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients.

30 Sep 2014

Greek survey shows women oncologists are largely under-represented in leadership positions

A growing number of oncologists in Greece are female, but women continue to be under-represented in leadership positions, according to a survey reported at the ESMO 2014 Congress.

30 Sep 2014

Combination treatment prevents disease progression in patients with advanced melanoma

New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.

30 Sep 2014

U-M researchers describe new approach to discovering potential cancer treatments

Researchers at the University of Michigan have described a new approach to discovering potential cancer treatments that requires a fraction of the time needed for more traditional methods.

30 Sep 2014

Johnson & Johnson inks definitive deal to acquire Alios BioPharma

Johnson & Johnson today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.

30 Sep 2014

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).

30 Sep 2014

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK today announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma.

30 Sep 2014

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy.

30 Sep 2014

ProMedica and Harbor team up to address growing community need for mental health services

Today ProMedica and Harbor announced plans to form a joint operating company (JOC) to address a growing community need for mental health services in northwest Ohio and southeast Michigan.

30 Sep 2014

Pemetrexed/docetaxel with cisplatin achieve similar progression-free survival in NSCLC patients

The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.

30 Sep 2014

Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.

30 Sep 2014

Groups urge Medicare to cover LDCT screening for adults at high risk for lung cancer

More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer.

30 Sep 2014

Research!America to recognize distinguished research advocates with Advocacy Awards

Research!America's 19th annual Advocacy Awards will honor distinguished research advocates who are trailblazers in advancing medical progress to improve the health and economic security of our nation. The event will take place on Wednesday, March 11, 2015, at the Andrew W. Mellon Auditorium in Washington, DC.

30 Sep 2014

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

30 Sep 2014

Cancer community joins coalition seeking Medicare coverage for CT lung cancer screening

30 Sep 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.

30 Sep 2014

CFDA clears Elekta's Versa HD radiation therapy system

Following US and European approvals of Elekta's Versa HD™ linear accelerator, the China Food and Drug Administration (CFDA) has cleared the radiation therapy system for sale and marketing in the country.

From Elekta 30 Sep 2014

Oncology News and Research

Further Reading

Dandrit Biotech A/S Signs Agreement To Commence Clinical Trials Of Melcancervac®

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Greek survey shows women oncologists are largely under-represented in leadership positions

Combination treatment prevents disease progression in patients with advanced melanoma

U-M researchers describe new approach to discovering potential cancer treatments

Johnson & Johnson inks definitive deal to acquire Alios BioPharma

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

ProMedica and Harbor team up to address growing community need for mental health services

Pemetrexed/docetaxel with cisplatin achieve similar progression-free survival in NSCLC patients

Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Groups urge Medicare to cover LDCT screening for adults at high risk for lung cancer

Research!America to recognize distinguished research advocates with Advocacy Awards

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Cancer community joins coalition seeking Medicare coverage for CT lung cancer screening

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

CFDA clears Elekta's Versa HD radiation therapy system

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News